Trofinetide Patent Expiration
Trofinetide is Used for treating Rett Syndrome or its symptoms. It was first introduced by Acadia Pharmaceuticals Inc
Trofinetide Patents
Given below is the list of patents protecting Trofinetide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Daybue |
US11827600 (Pediatric) | Crystalline Forms Of Trofinetide | Jan 12, 2043 | Acadia Pharms Inc |
| Daybue |
US12492167 (Pediatric) | Crystalline Forms Of Trofinetide | Jan 12, 2043 | Acadia Pharms Inc |
| Daybue Stix |
US11827600 (Pediatric) | Crystalline Forms Of Trofinetide | Jan 12, 2043 | Acadia Pharms Inc |
| Daybue Stix |
US12492167 (Pediatric) | Crystalline Forms Of Trofinetide | Jan 12, 2043 | Acadia Pharms Inc |
| Daybue | US11827600 | Crystalline forms of trofinetide | Jul 12, 2042 | Acadia Pharms Inc |
| Daybue | US12492167 | Crystalline Forms Of Trofinetide | Jul 12, 2042 | Acadia Pharms Inc |
| Daybue Stix | US11827600 | Crystalline forms of trofinetide | Jul 12, 2042 | Acadia Pharms Inc |
| Daybue Stix | US12492167 | Crystalline Forms Of Trofinetide | Jul 12, 2042 | Acadia Pharms Inc |
| Daybue |
US11370755 (Pediatric) | Compositions Of Trofinetide | Feb 03, 2041 | Acadia Pharms Inc |
| Daybue Stix |
US11370755 (Pediatric) | Compositions Of Trofinetide | Feb 03, 2041 | Acadia Pharms Inc |
| Daybue | US11370755 | Compositions of trofinetide | Aug 03, 2040 | Acadia Pharms Inc |
| Daybue Stix | US11370755 | Compositions of trofinetide | Aug 03, 2040 | Acadia Pharms Inc |
| Daybue |
US9212204 (Pediatric) | Treatment Of Rett Syndrome Using Glycyl-L-2-Methylprolyl-L-Glutamic Acid | Jul 27, 2032 | Acadia Pharms Inc |
| Daybue Stix |
US9212204 (Pediatric) | Treatment Of Rett Syndrome Using Glycyl-L-2-Methylprolyl-L-Glutamic Acid | Jul 27, 2032 | Acadia Pharms Inc |
| Daybue | US9212204 | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid | Jan 27, 2032 | Acadia Pharms Inc |
| Daybue Stix | US9212204 | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid | Jan 27, 2032 | Acadia Pharms Inc |
Trofinetide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Trofinetide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome | Unravel Biosciences, Inc. | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |